Cargando…
Oncolytic Viruses in the Treatment of Bladder Cancer
Bladder carcinoma is the second most common malignancy of the urinary tract. Up to 85% of patients with bladder cancer are diagnosed with a tumor that is limited to the bladder mucosa (Ta, T1, and CIS). These stages are commonly termed as non-muscle-invasive bladder cancer (NMIBC). Although the trea...
Autores principales: | Potts, Kyle G., Hitt, Mary M., Moore, Ronald B. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi Publishing Corporation
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3414001/ https://www.ncbi.nlm.nih.gov/pubmed/22899907 http://dx.doi.org/10.1155/2012/404581 |
Ejemplares similares
-
Deletion of F4L (ribonucleotide reductase) in vaccinia virus produces a selective oncolytic virus and promotes anti‐tumor immunity with superior safety in bladder cancer models
por: Potts, Kyle G, et al.
Publicado: (2017) -
Radiation-Induced Cellular Senescence Reduces Susceptibility of Glioblastoma Cells to Oncolytic Vaccinia Virus
por: Storozynsky, Quinn T., et al.
Publicado: (2023) -
Genetic Modifications That Expand Oncolytic Virus Potency
por: Cristi, Francisca, et al.
Publicado: (2022) -
Oncolytic Viruses for the Treatment of Bladder Cancer: Advances, Challenges, and Prospects
por: Hu, Henglong, et al.
Publicado: (2022) -
Targeting Nucleotide Biosynthesis: A Strategy for Improving the Oncolytic Potential of DNA Viruses
por: Irwin, Chad R., et al.
Publicado: (2017)